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OBJECTIVE — Recent epidemiological studies suggested that some insulin analogues could
beassociatedwithincreasedriskofcancer.Thepresentstudyisaimedatassessingthelong-term
association of different insulin analogues with cancer incidence.
RESEARCH DESIGN AND METHODS — A nested case-control study dataset was
generated from the cohort study dataset (n  1,340 insulin-treated diabetic outpatients) by
sampling control subjects from the risk sets. For each case subject, the control subjects (up to
ﬁve) were chosen randomly from those members of the cohort who are at risk for the same
follow-uptimeofthecasesubject.Five-yearageclasses,sex,andBMIclasses(18.5,18.5–24.9,
25–29.9, and 30 kg/m
2) were considered as additional categorical matching variables.
RESULTS — During a median follow-up of 75.9 months (interquartile range 27.4–133.7),
112 case subjects of incident cancer were compared with 370 matched control subjects. A
signiﬁcantly higher mean daily dose of glargine was observed in case subjects than in control
subjects (0.24 IU/kg/day [0.10–0.39] versus 0.16 IU/kg/day [0.12–0.24], P  0.036). Incident
cancer was associated with a dose of glargine 0.3 IU/kg/day even after adjusting for Charlson
comorbidity score, other types of insulin administration, and metformin exposure (odds ratio
5.43 [95% CI 2.18–13.53], P  0.001). No association between incident cancer and insulin
doses was found for human insulin or other analogues.
CONCLUSIONS — The possibility of association between cancer and higher glargine doses
suggests that dosages should always be considered when assessing the possible association of
insulin and its analogues with cancer.
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L
ong-acting insulin analogues,
glargine and detemir, were intro-
ducedforprovidingbasalinsuliniza-
tion with a lower hypoglycemic risk than
NPH insulin (1). Recent epidemiological
studies suggested an association of
glargine with malignancies (2–4) and
particularly with breast cancer (2,4), pos-
sibly in a dose-dependent fashion (3).
These results, not conﬁrmed by other in-
vestigators (5), have been widely criti-
cizedforsomemethodologicallimitations
(6,7) either in the quality of administra-
tive data used for analyses (6) or their sta-
tistical management (7). Moreover,
patients receiving prescriptions for differ-
ent analogues might differ for clinical
characteristics, potentially accounting for
diversities in cancer incidence, such a
prescription bias could be particularly
relevant in register-based studies, which
allowadjustmentsforalimitednumberof
confounders. Furthermore, the compari-
son of the basal insulin glargine with hu-
man insulin, which includes both basal
and prandial formulations, could reﬂect
diversities between treatment regimens
rather than actual differences between
human insulin and its analogues. The in-
creased risk of malignancies observed in
patients using glargine only was not con-
ﬁrmed in those treated with combinations
of glargine and other insulins (2–4). The
short duration of observation in the above-
cited studies represents a further limitation,
considering the long incubation period
characterizing most malignancies.
The present investigation is aimed at
assessing the long-term association be-
tween incidence of cancer and use of dif-
ferent insulin analogues, considering
insulin doses and a larger number of con-
founders than those included in previous
studies.Amainproblemofpreviousstud-
ies was the management of variations of
insulin therapy during follow-up, which
becomes more relevant with a longer ob-
servation; some studies (2,4) analyzed
baseline therapy, missing relevant infor-
mation, while another (3) applied ques-
tionable statistical models, using
therapies during follow-up as if they were
baseline variables. A nested case-control
design,usingamultipleconditionallogis-
tic regression model, was used in order to
overcomethoselimitations.Furthermore,
doses for each insulin treatment were
considered as a possible moderator of the
effect of each insulin type (1).
RESEARCH DESIGN AND
METHODS— Within a cohort of in-
sulin-treated type 2 diabetic patients,
those with incident cancer during a lon-
gitudinal follow-up were identiﬁed as
case subjects and compared for treat-
ments received with matched control
subjects from the same cohort.
Of a consecutive series of 1,533 dia-
betic outpatients, referred to the diabetes
clinics of the University of Florence, Italy,
and starting insulin therapy between
1 January 1998 and 31 December 2007,
those free of previous malignancies (n 
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vided that they met the following criteria:
1. They were living in the city of Flo-
rence at the date of enrolment;
2. They had a clinical diagnosis of type 2
diabetes;
3. They had no reported insulin therapy
during the previous 5 years; and
4. Theyhadnoreportedpreviousmalig-
nancy or hospital admission for ma-
lignancy after 1 January 1998 and
before initiation of insulin therapy.
The participating hospital-based clinics
provided outpatient care for diabetes; a
largemajorityofpatientsinitiatinginsulin
therapy are referred to specialist clinics,
which also provided subsequent follow-
ups,atleastyearly.Allpatientsweretreated
byspecialistswhodidnotreceiveincentives
for the use of less expensive drugs.
Demographic and clinical informa-
tion was obtained from clinical records,
including a detailed medical history, self-
reported smoking habits and alcohol in-
take, prescribed medications, A1C
(measured every 3–4 months with high-
perfomance liquid chromatography
[Menarini Diagnostics, Florence, Italy],
upper normal limit 5.9%), lipid proﬁle,
and serum creatinine, and assessed as a
partofroutinefollow-up.Weight,height,
and blood pressure were routinely mea-
suredateachvisitfollowingWorldHealth
Organization recommendations (8). The
nearest-available measure within a
3-month interval from enrollment was
usedasthebaselinevalueforeachparam-
eter. Alcohol abuse was deﬁned as a con-
sumption exceeding two drinks per day.
ComorbiditywasassessedwiththeCharl-
son comorbidity score (CCS), which in-
cludes diabetes and its complications,
malignancies, arthritis/arthrosis, HIV-
infections, chronic cardiovascular dis-
ease, skin ulcers, renal insufﬁciency, liver
diseases, and obstructive pulmonary dis-
ease (9).
Patients were observed until 31 De-
cember 2008 or to the date in which they
moved to another city. Cancer incident
case subjects were identiﬁed as ﬁrst hos-
pital admission or death with ICD-9
codes 140–209. Information on hospital
admission was obtained through the Re-
gional Hospital Discharge System, an ad-
ministrative database containing ICD
codesofcurrentdiagnoses,whichcollects
all reimbursed admissions (in public or
private hospitals), with no possibility of
loss at follow-up. Deaths from cancer
wereobtainedfromtheMortalityRegistry
of Tuscany. Patients with previous malig-
nancies at ﬁrst visit (n  193) were ex-
cluded. Case ﬁnding was therefore
performedon1,340patients(746women
and 594 men), aged (means  SD)
63.1  14.9 years, with a median dura-
tion of diabetes of 7.5 years (interquartile
range 0.5–19.2), A1C 8.7  1.9%, and
BMI 27.9  5.4 kg/m
2.
A nested case-control study dataset
wasgeneratedfromthecohortstudydata-
set by sampling control subjects from the
risk sets. For each case subject, the con-
trol subjects (up to ﬁve) were chosen ran-
domly from those members of the cohort
who are at risk for the same follow-up
time of the case subject. The resulting
case-control sample is therefore matched
with respect to analysis time. Five-year
age classes, sex, and BMI classes (18.5,
18.5–24.9, 25–29.9, and 30 kg/m
2)
were considered as additional categorical
variables for matching control subjects to
case subjects. We used the STATA 9.0
software and the procedure “sttocc,”
which takes into account survival times,
to implement this step.
Hypoglycemic treatments
Exposure to hypoglycemic drugs was as-
sessedfromenrollmenttoincidentcancer
in case subjects and during the corre-
sponding time from initiation of insulin
therapy in matched control subjects. To
comparecaseandcontrolsubjectsfordif-
ferences in exposure to each insulin type,
the mean daily dose (MDD) was calcu-
lated, dividing total insulin units pre-
scribed for duration of observation (days)
and for weight (kg), thus accounting for
both time of treatment and daily dose
during treatment.
MDD was calculated separately for
basal and prandial formulations of each
insulin.Forpremixedinsulin,thefraction
of the dose attributed to basal or prandial
therapy was calculated and used in sub-
sequent analyses. For oral hypoglycemic
drugs, the length of exposure during the
10yearsprecedingtheendofobservation
was considered. Drug exposure was ob-
tained from clinical records containing a
self-reported history of hypoglycemic
treatment before the ﬁrst contact and all
drug prescriptions afterward. Informa-
tion retrieval for each case and control
subject was performed independently by
two investigators, and conﬂicts were re-
solvedbyathirdinvestigator(E.M.).Ifthe
last available visit had occurred 3
months before the event (or the matching
index date), a telephone contact was at-
tempted to collect further information on
subsequent drug use; if unsuccessful, the
patient was assumed to have continued
the last reported therapy. Three cases
with a last visit occurring 2 years from
the end of follow-up were excluded from
analysis.
Statistical analysis
The main predeﬁned analysis was the
comparison of case and control subject
for proportion of patients exposed and
MDD(units/kg/day)foreachinsulin.Fur-
ther multivariate analyses were designed
on the basis of those results. Unpaired
Student t test and Mann-Whitney test
were used to compare continuous vari-
ables whenever appropriate. 
2 Test was
used for between-group comparisons of
categorical variables. The statistical anal-
ysis was done by conditional logistic re-
gression, which takes into account the
matching structure. This was especially
importantbecauseforsomecasesubjects,
less than ﬁve control subjects were avail-
able in the risk set, so that an unequal
number of control subjects were sampled
bycasesubject.Inallmodels,totalinsulin
MDD, CCS, and metformin exposure
were used as covariates, along with MDD
and proportion of subjects with MDD
0.3 IU/kg/day for each insulin type. Al-
ternative models in which MDD for basal
and prandial insulins were entered sepa-
rately were applied. Furthermore, an
analysis with CCS, metformin exposure,
total insulin MDD, glargine exposure
time, and mean glargine dose during ex-
posure was performed. All analyses were
carried out with SPSS 15.0 statistical
package and STATA 9.0, and a P  0.05
was considered statistically signiﬁcant.
RESULTS— During a median fol-
low-up of 75.9 months (interquartile
range27.4–133.7),112patientshadnew
diagnoses of cancer (incidence 1.9/100
person-years); in 1 case subject, 2 differ-
ent cancers were observed, for a total
number of 113 registered cancers (11
colorectal, 18 other gastrointestinal/
hepatic,14pancreatic,16lung,10leuke-
mia/lymphoma, 7 breast, 5 female
urogenital,9maleurinary,4prostate,and
20 other cancers).
Thedemographicandclinicalcharac-
teristics of case and control subjects are
summarizedinTable1.Casesubjectshad
a greater comorbidity and a nonsigniﬁ-
cant trend toward less exposure to met-
formin in the previous 10 years, whereas
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[interquartile range]) was not signiﬁ-
cantly different between case and control
subjects (16.0 mg/kg/day [11.8–21.4] vs.
18.2 mg/kg/day [10.0–20.9], P  0.63).
After adjusting for CCS and mean daily
total insulin dose, time of exposure to
metformin(hazardratio[HR]0.993[95%
CI 0.986–0.999], P  0.046, for
eachmonth)andmetformindoses(0.943
[0.915–0.971],P0.01,foreachmg/kg/
day) were both inversely associated with
incident cancer. The proportion of pa-
tients who discontinued insulin treat-
mentduringfollow-upwassimilarincase
andcontrolsubjects(34.3vs.41.2%,P
0.54).
No signiﬁcant difference was ob-
served between case and control subjects
in the proportion of patients exposed to
eachinsulin.Amongthoseexposed,asig-
niﬁcantly higher MDD (IU/kg/day) was
observed in case subjects than in control
subjects for glargine only. In those receiv-
ing glargine, median duration of glargine
treatment was 20.0 months (9.0–28.0)
and 14.5 months (4.7–26.0) in case and
control subjects, respectively (P  0.16);
correspondingﬁguresforhumanbasalin-
sulin were 19.4 months (5.7–48.2) and
21.0 months (7.0–45.7) (P  0.86). The
proportion of patients receiving 0.3 IU/
kg/day of glargine was higher in case sub-
jects (13/112 [11.6%] vs. 14/370 [3.8%],
P  0.002), whereas no such difference
was observed for human insulin (27/112
[24.1%] vs. 107/370 [28.8%], P  0.33),
lispro (19/112 [17.0%] vs. 92/370
[24.9%], P  0.08), or aspart (2/112
[1.8%] vs. 2/370 [4.2%], P  0.24). Me-
dian doses of basal insulin did not differ
between case and control subjects (0.16
[0.08–0.31] vs. 0.16 [0.07–027], P 
0.59).Meantotalinsulindosewasnotsig-
niﬁcantlydifferentbetweencaseandcon-
trol subjects, even after adjusting for
metformin exposure and CCS (odds ratio
1.024 [95% CI 0.946–1.108], P  0.56,
for each 0.1 IU/kg/day increment in
MDD). After adjusting for the same con-
founders, exposure to a mean daily total
insulin dose 0.3 IU/kg/day was not sig-
niﬁcantly associated with incident cancer
(HR0.75[95%CI0.50–1.17],P0.21).
A majority of patients were treated
withcombinationsofbasalandprandial
insulin at some time during follow-up,
in both case and control subjects. In
particular, 82.9 and 86.2% of patients
receiving glargine were also exposed to
prandialinsulinamongcaseandcontrol
subjects, respectively; the correspond-
Table 1—Main demographic and clinical characteristics of enrolled sample
Case subjects Control subjects P
n (male/female) 112 (60/52) 370 (189/181) 0.64
Age (years) 68.9  9.9 68.0  10.0 0.41
Duration of diabetes (years) 8.4 (0.3–20.9) 10.0 (0.6–21.0) 0.28
BMI (kg/m
2) 28.1  5.3 28.2  5.1 0.78
Weight (kg) 75.5  14.2 75.8  16.5 0.47
Systolic blood pressure (mmHg) 142.5  20.9 141.5  21.6 0.71
Diastolic blood pressure (mmHg) 80.4  10.0 79.8  11.2 0.42
Alcohol abuse 15 (13.4) 40 (10.8) 0.61
Current smokers 25 (22.5) 66 (17.8) 0.39
CCS 2.4  1.4 2.1  1.1 0.035
Laboratory parameters
A1C (%) 8.5  1.9 8.5  1.8 0.99
Total cholesterol (mg/dl) 195.8  47.3 208.9  44.3 0.029
HDL cholesterol (mg/dl) 47.1  15.3 52.6  15.5 0.031
Triglycerides (mg/dl) 143.0 (108.0–93.0) 138.0 (95.7–196.2) 0.61
Creatinine (mg/dl) 1.1  0.4 1.1  0.5 0.99
Microalbuminuria (g/ml) 13.0 (5.4–44.8) 11.0 (5.7–31.0) 0.82
Medical history
Ischemic heart disease 30 (26.8) 79 (21.4) 0.23
Cerebrovascular disease 5 (4.5) 25 (6.8) 0.38
Renal failure 9 (8.0) 26 (7.0) 0.72
Retinopathy 10 (8.9) 75 (20.3) 0.006
Neuropathy 31 (27.7) 103 (27.8) 0.97
Foot ulcers 3 (2.7) 22 (5.9) 0.17
Chronic obstructive pulmonary
disease
7 (6.3) 23 (6.2) 0.99
Any liver disease 16 (14.3) 27 (7.3) 0.10
Microalbuminuria 18 (16.1) 68 (18.4) 0.58
Pharmacological therapy at
enrollment
Antihypertensive drugs 60 (53.6) 212 (57.3) 0.58
Statins 30 (26.7) 86 (23.2) 0.62
Antiaggregants 46 (41.0) 155 (41.9) 0.81
Oral hypoglycaemic drugs
Any exposure during the previous
10 years
Metformin 70 (62.5) 228 (61.6) 0.86
Insulin secretagogues 65 (58.0) 199 (53.8) 0.48
Thiazolidinediones 1 (0.9) 11 (3.0) 0.21
Length of exposure during the
previous 10 years (months)*
Metformin 27.5 (9.0–61.0) 40.0 (13.2–73.76) 0.08
Insulin secretagogues 20.2 (5.5–77.5) 50.0 (10.5–67.5) 0.59
Patients exposed during follow-up
Any exposure
Human insulin 82 (73.2) 245 (66.2) 0.16
Basal 26 (23.2) 74 (20.0) 0.46
Prandial 78 (69.6) 231 (62.4) 0.16
Lispro 53 (47.3) 184(49.7) 0.65
Basal 1 (0.9) 3 (0.8) 0.93
Prandial 53 (47.3) 180 (48.6) 0.80
Aspart 9 (8.0) 34 (9.2) 0.71
Basal 0 (0.0) 0 (0.0) —
Detemir 1 (0.9) 13 (3.5) 0.14
Glargine 29 (26.0) 105 (28.4) 0.61
(continued)
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58.9 and 55.1%. Of those treated with
glargine, 23.8 and 37.9% in control and
casesubjects,respectively,alsoreceived
NPH at some time during follow-up; a
large majority (94.5%) of those were
treated initially with NPH and with
glargine afterward.
Theassociationof0.3IU/kg/dayin-
sulin doses, adjusted for CCS, metformin
exposure, and mean daily total insulin
dose, is reported in Fig. 1 for each prepa-
ration, with the exception of detemir and
basal lispro, which could not be analyzed
for insufﬁcient case numbers. At total of
0.3 IU/kg/day basal insulin was associ-
ated with incident cancer; this phenome-
non was due to the association of cancer
with high-dose glargine, which was not
observed with basal (NPH) human insu-
lin. In fact, 0.3 IU/kg/day glargine was
associated with increased risk of cancer,
while no effect was observed for human
insulinoraspart;thisassociationwascon-
ﬁrmed after exclusion from analysis of
cases with cancer occurring within the
ﬁrst12monthsofobservationandoftheir
corresponding matched control subjects
(Fig. 1). After adjusting for confounders,
lispro was associated with a marginally
lower risk of cancer, which was not con-
ﬁrmed after exclusion of cases occurring
within the ﬁrst 12 months of observation.
An alternative model, adjusting for met-
formin exposure, CCS, exposure to pran-
dial insulin, and doses of other basal
insulins, provided similar results (odds
ratio 4.76 [95% CI 1.99–11.40], P 
0.001, and 0.73 [0.34–1.53], P  0.40,
for glargine and NPH, respectively). In a
further model, adjusting for the same
confounders plus any exposure to other
basal insulins during follow-up, use of
0.3 IU/kg/day glargine was still associ-
atedwithcancer(5.83[2.34–14.30],P
0.001).
The association of 0.3 IU/kg/day
glargine with incident cancer was evident
in younger, but not in older, subjects,
whileitwassimilarinmenandwomenand
in leaner and overweight/obese patients
(Fig. A-1 in the online appendix, available
at http://care.diabetesjournals.org/cgi/
content/full/dc10-0476/DC1). Consider-
ing different cancer types, the odds ratio
for breast cancer (n  7) was 5.46 (95%
CI0.45–66.1)(P0.18);corresponding
ﬁgures for gastrointestinal/hepatic (n 
29),pulmonary(n16),pancreatic(n
14), and leukemia/lymphoma (n  10)
were 0.58 [0.06–5.87], 2.89 [0.37–
22.23], 4.00 [0.25–63.95], and 2.83
[0.17–47.15], respectively.
When insulin doses (IU/kg/day) were
considered as a continuous variable, no
signiﬁcant unadjusted association be-
tween MDDs and risk of incident cancer
was found for any insulin preparation, al-
though a nonsigniﬁcant trend could be
observedforglargine.Whenadjustingfor
totalinsulindose,comorbidity,andexpo-
sure to metformin, glargine (adjusted
odds ratio 1.33 [95% CI 1.07–1.65], P 
0.011,foreach0.1IU/kg/dayincrement),
but not basal human insulin (1.06 [0.91–
1.24], P  0.11), was associated with a
greater risk of incident cancer; similar re-
sults were obtained when adding current
smokingasacovariate(1.35[1.04–1.76],
P  0.020, and 1.04 [0.87–1.29], P 
Figure 1—Risk of cancer associated with doses of each insulin type 0.3 IU/kg/day, adjusted for
comorbidity, exposure to metformin, and doses of other types of insulin. E, all case subjects; F,
afterexclusionofcasesubjectswithcanceroccurringwithintheﬁrst12monthsofobservationand
of their matched control subjects.
Table 1—Continued
Case subjects Control subjects P
MDD (IU/day)*
Human insulin 13.9 (8.0–29.9) 17.7 (8.0–29.9) 0.40
Basal 11.0 (6.2–19.0) 12.1 (6.9–20.9) 0.45
Prandial 14.2 (9.1–24.8) 16.1 (8.0–33.0) 0.83
Lispro 20.1 (10.2–30.2) 22.0 (10.5–30.0) 0.93
Basal 7.0 (7.0–7.0) 3.9 (2.4–33.7) 0.71
Prandial 20.1 (8.7–30.2) 22.0 (10.5–30.0) 0.91
Aspart 16.0 (9.2–24.0) 25.2 (15.0–31.4) 0.11
Glargine 17.1 (7.0–30.6) 12.1 (8.0–18.0) 0.08
Total 27.1 (14.0–42.0) 27.9 (14.7–43.2) 0.71
MDD (IU/kg/day)*
Human insulin 0.19 (0.10–0.38) 0.24 (0.11–0.40) 0.40
Basal 0.15 (0.09–0.24) 0.17 (0.09–0.28) 0.86
Prandial 0.21 (0.10–0.36) 0.23 (0.11–0.37) 0.61
Lispro 0.26 (0.13–0.46) 0.30 (0.15–0.43) 0.48
Basal 0.12 (0.12–0.12) 0.05 (0.03–0.51) 0.37
Prandial 0.26 (0.13–0.46) 0.30 (0.15–0.43) 0.91
Aspart 0.25 (0.11–0.29) 0.30 (0.20–0.44) 0.33
Glargine 0.24 (0.10–0.39) 0.16 (0.12–0.24) 0.036
Total 0.35 (0.20–0.59) 0.39 (0.20–0.59) 0.75
Data are expressed as means  SD, median (interquartile range), or n (%). *In exposed patients.
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glargineandhumanbasalinsulin,respec-
tively). This association was maintained
after exclusion of case subjects occurring
in the ﬁrst 12 months of observation and
of their matching control subejects (1.34
[1.04–1.73], P  0.024, for each 0.1 IU/
kg/dayincrement).Tobetterdiscriminate
the effect of duration of treatment with
glargine and daily dose during treatment,
an alternative analysis was performed en-
tering those two variables together with
CCS,metforminexposure,andtotalinsu-
lin dose; incident cancer was associated
with higher mean glargine dose during
treatment (1.21[1.01–1.47], P  0.047,
for each 0.1 IU/kg/day) but not with du-
ration of glargine exposure (0.99 [0.97–
1.01], P  0.41, for each month).
CONCLUSIONS — The proportion
of case subjects exposed to each insulin
wasnotdifferentfromthatofcontrolsub-
jects, whereas higher MDDs of glargine,
but not of other types of insulin, were as-
sociated with cancer after adjusting for
confounders.
Several hypoglycemic agents have
beenreportedtomodifytheriskofmalig-
nancies in type 2 diabetic patients (10–
14). The link between hypoglycemic
treatment and cancer has been suggested
only by observational studies; however,
randomized clinical trials, designed to as-
sess the effects of drugs on metabolic
and/or cardiovascular outcomes, cannot
have an adequate sample size and length
of follow-up to provide relevant informa-
tion on incident malignancies.
In observational studies, different
agents are prescribed to patients with dif-
ferent characteristics, and those diversi-
ties cannot be entirely eliminated by
statistical adjustments (6,7). Previous
studiessuggestinganassociationbetween
glargine and cancer (2–4) suffered from
further limitations, including limited in-
formation on comorbidities (2–4), short
duration of observation, the inclusion of
probably pre-existing cases of cancer
diagnosed shortly after the initiation of
insulin (2,3,5), and the failure to discrim-
inate between basal and prandial human
insulin used as comparator (2–4). In one
study (3), the inclusion of time-
dependent covariates within a traditional
Cox model (7) could have interfered with
results (2). On the other hand, because of
thefrequentchangeofinsulinregimensin
clinical practice, the use of baseline ther-
apy for analysis (2,4,5) is a limitation in
studies with longer follow-up.
The present study was designed to
overcome, at least partly, those limita-
tions. The prolonged follow-up allowed
to identify relevant numbers of incident
case subjects whose onset reasonably oc-
curred after the initiation of insulin ther-
apy. The persistent association of high-
dose glargine with cancer after exclusion
of cases occurring within the ﬁrst 12
months of observation suggests that differ-
ences cannot be attributed to pre-existing,
but still subclinical, malignancies. The ad-
justmentforacomorbidityindexconﬁrms
that treatment-related differences in can-
cer incidence cannot be considered the
effect of comorbid conditions. Moreover,
the association of high-dose glargine with
incident cancer cannot be regarded as a
“class effect” of any formulation of basal
insulin or as a consequence of the charac-
teristics of patients prescribed any type of
basalinsulin,sinceitwasnotobservedfor
basal (NPH) human insulin.
Several observational studies have
shown that oral hypoglycemic treatments
can be associated either with increased or
reduced incidence of cancer (10–14). In
particular, a dose-dependent inverse as-
sociation of metformin with incident
cancer has been reported (11,12) and
conﬁrmed in our sample. Notably, the as-
sociation of high-dose glargine with can-
cerwasconﬁrmedevenafteradjustingfor
metformin exposure.
Arecentmeta-analysisofrandomized
clinical trials failed to show any associa-
tion between glargine and cancer (15),
butthelimitednumberofcasesproduced
wide CIs in risk estimates. The short du-
ration of most randomized trials is a fur-
ther limitation to that meta-analysis.
These considerations also apply to an-
other meta-analysis showing a lower inci-
dence of cancer with detemir than with
human NPH insulin (16). The two meta-
analyses enrolled both type 1 and type 2
diabetic patients, limiting their interpre-
tation for each of those two individual
conditions.
Short-acting insulin analogues, lispro
and aspart, did not appear to be associ-
atedwithahigherriskthanprandial(reg-
ular) human insulin. The limited
proportion of patients treated with aspart
suggests a special caution in the interpre-
tation of results on this analog, while data
on detemir were too limited to provide
any valuable information.
Two previous studies (2,4) reported
an association of glargine with breast can-
cer but not with other types of malig-
nancy. The present sample does not have
anadequatesizetoprovidedetailedinfor-
mation on speciﬁc types of tumors; al-
though it is possible that glargine
treatment has a greater association with
breast cancer, the signiﬁcant association
between high-dose glargine and cancer in
men suggests that malignancies other
than breast cancer could be involved.
Discrepanciesbetweenthepresentre-
sults and some previous data (2,4,5)
could have been determined, at least in
part, by differences in duration of follow-
up. It should be recognized that even the
longer follow-up of this study could be
insufﬁcient to detect differences with re-
spect to cancer incidence. Furthermore,
we observed a dose-dependent associa-
tion of glargine with incident malignan-
cies, consistent with one previous
observation (3).
The mechanisms that could account
for differences in cancer risk in type 2 di-
abeticpatientstreatedwithdifferenttypes
of insulin are uncertain. The mitogenic
properties of glargine observed in some
preclinical models (17–19), but not con-
sistently conﬁrmed in others (20,21),
have been reported to be either speciﬁc
for glargine (18,19) or shared with other
insulin analogues (19). Compared with
human insulin, glargine has a higher af-
ﬁnity for the IGF-1 receptor, which could
translate into a greater stimulation of cell
growth and transformation, leading to in-
creasedcancerrisk(17);however,theim-
pact of the IGF-1 axis on malignancies is
still controversial (22). Furthermore, in-
sulin,particularlywhenathighdoses,has
a mitogenic and transforming effect inde-
pendent of its interaction with the IGF-1
receptor(23).Inthepresentstudy,higher
doses of insulin other than glargine were
not associated with incident cancer, but
this result could be due to an insufﬁcient
sample size.
Some further limitations of our study
should be acknowledged. No detailed in-
formation on reproductive history in
women, potentially affecting the inci-
dence of breast cancer, was available. In-
formation on treatments was based on
drug prescription, rather than output
from pharmacies, as in previous studies
(2–5); in the case of reduced compliance,
this should lead to overestimating actual
insulin consumption. However, assess-
ment of insulin delivered from pharma-
cies could also overestimate actual
exposure,becauseafractionoftheinsulin
bought in pharmacies is wasted for sev-
eral reasons. It is possible that patients
receiving higher basal insulin doses were
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chance of receiving glargine instead of
NPH, although median basal insulin
doses did not differ between case and
control subjects. It should also be consid-
ered that cases of incident cancer were
identiﬁed through hospital admissions
and death certiﬁcates so that few cases of
nonfatal malignancies not receiving treat-
ment in public hospitals could have been
missed. Furthermore, the choice of 0.3
IU/kg/day as a threshold for high-dose
treatment is somewhat arbitrary; a larger
sample size is needed for exploring more
thoroughly the dose-response relation-
ship, identifying a more reliable cutoff.
Anotherrelevantlimitationisrepresented
by the observational nature of our study,
which prevents the entire elimination of
prescriptionbiases,althoughthemultiple
adjustments performed attenuate the
problem.Notably,localguidelines(www.
siditalia.it)recommendeitherNPHoran-
alogues as basal insulins, recognizing that
the former is associated with higher hy-
poglycemic risk. Some potentially rele-
vant confounders affecting treatment
choices,suchasinsulinresistance,arenot
available. Further, glargine insulin could
have been used as a rescue therapy in
cases not adequately controlled with
other, less expensive, insulin prepara-
tions, such as NPH, making glargine a
marker of severity of disease. This is a rel-
evant issue, considering that diabetes it-
self is associated with increased risk of
cancer. It should also be considered that
available evidence shows that glargine re-
duces the risk of hypoglycemia without
improving A1C (1), as stated also in Ital-
ian national guidelines (www.siditalia.it);
therefore, the shift from NPH to glargine
is likely to be motivated by hypoglycemic
episodes, rather than to inadequate con-
trol of fasting glucose. Furthermore, the
associationbetweenuseofhigherglargine
doses and incident cancer was conﬁrmed
after adjusting for previous therapy with
NPH insulin.
We should all be aware that the ep-
idemiological approach cannot provide
deﬁnitive conclusions on the effects of
any pharmacological treatment. In fact,
not all the motivations underlying a
therapeuticdecisioncanbeformallyex-
plored and adjusted for in multivariate
analyses. For example, patients treated
with insulin analogues (either basal or
prandial) could be different for some
clinical or sociocultural characteristics
not reported in clinical records; how-
ever, only high-dose glargine, and not
other (rapid-acting) analogues, was as-
sociated with incident cancer. The only
fully reliable instrument to assess the
effects of glargine on the incidence of
cancer would be an adequately sized,
long-term, randomized trial with other
basal insulins as active comparators and
the onset of malignancies as the pre-
deﬁned, primary end point. Unfortu-
nately, such a trial is not likely to be
performed, so that information on safety
of glargine, and of other insulin ana-
logues, will inevitably derive from obser-
vational studies, such as the present one.
Clinical decisions should be based on
a careful evaluation of risk/beneﬁt (and
cost/beneﬁt)ratios.Glarginehassomead-
vantages over NPH human insulin, such
as a lower risk of nocturnal hypoglycemia
in head-to-head comparisons (1). The
only other available long-acting insulin
analog,detemir,isabsorbedmorerapidly
after subcutaneous injection and it has
therefore a shorter duration of action
(24); as a consequence, many patients
treated with detemir need a twice-daily
administration, while glargine usually is
effective with once-a-day administration
(25). Conversely, long-acting insulin an-
alogues have a higher cost than NPH in-
sulin. The potentially greater risk for
cancer with glargine should be weighed
against those advantages. Further, larger-
scaleobservationalstudiesontheincidence
of malignancies in patients treated with
glargine should be performed taking into
account insulin doses, in order to quantify
the actual impact of different insulin ana-
logues on the onset of new cases of cancer
and identify patients at higher risk.
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